Bristol-Myers Squibb Co (BMY)
44.70
-4.16
(-8.51%)
USD |
NYSE |
Apr 25, 16:00
44.99
+0.29
(+0.65%)
Pre-Market: 04:50
Bristol-Myers Squibb Enterprise Value: 117.94B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 117.94B |
| April 24, 2024 | 126.35B |
| April 23, 2024 | 126.61B |
| April 22, 2024 | 126.92B |
| April 19, 2024 | 126.49B |
| April 18, 2024 | 125.22B |
| April 17, 2024 | 124.29B |
| April 16, 2024 | 125.14B |
| April 15, 2024 | 125.64B |
| April 12, 2024 | 125.18B |
| April 11, 2024 | 126.88B |
| April 10, 2024 | 129.24B |
| April 09, 2024 | 131.89B |
| April 08, 2024 | 130.88B |
| April 05, 2024 | 131.33B |
| April 04, 2024 | 131.49B |
| April 03, 2024 | 133.07B |
| April 02, 2024 | 134.20B |
| April 01, 2024 | 134.70B |
| March 28, 2024 | 137.21B |
| March 27, 2024 | 135.23B |
| March 26, 2024 | 133.81B |
| March 25, 2024 | 133.21B |
| March 22, 2024 | 132.56B |
| March 21, 2024 | 131.87B |
| Date | Value |
|---|---|
| March 20, 2024 | 132.46B |
| March 19, 2024 | 132.30B |
| March 18, 2024 | 131.87B |
| March 15, 2024 | 133.39B |
| March 14, 2024 | 133.69B |
| March 13, 2024 | 134.02B |
| March 12, 2024 | 137.55B |
| March 11, 2024 | 137.47B |
| March 08, 2024 | 136.32B |
| March 07, 2024 | 135.29B |
| March 06, 2024 | 135.49B |
| March 05, 2024 | 132.34B |
| March 04, 2024 | 130.52B |
| March 01, 2024 | 130.46B |
| February 29, 2024 | 130.17B |
| February 28, 2024 | 130.52B |
| February 27, 2024 | 129.69B |
| February 26, 2024 | 129.71B |
| February 23, 2024 | 132.01B |
| February 22, 2024 | 131.35B |
| February 21, 2024 | 130.50B |
| February 20, 2024 | 128.37B |
| February 16, 2024 | 128.37B |
| February 15, 2024 | 127.52B |
| February 14, 2024 | 126.41B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.68B
Minimum
Jul 22 2019
202.63B
Maximum
Dec 02 2022
155.87B
Average
165.68B
Median
Jun 02 2020
Enterprise Value Benchmarks
| Amgen Inc | 198.03B |
| Gilead Sciences Inc | 98.95B |
| Johnson & Johnson | 360.21B |
| Karuna Therapeutics Inc (DELISTED) | 11.34B |
| 2seventy bio Inc | 3.136M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.762B |
| Revenue (Quarterly) | 11.48B |
| Total Expenses (Quarterly) | 9.574B |
| EPS Diluted (Quarterly) | 0.87 |
| Gross Profit Margin (Quarterly) | 76.08% |
| Profit Margin (Quarterly) | 15.35% |
| Earnings Yield | 8.64% |
| Operating Earnings Yield | 8.82% |
| Normalized Earnings Yield | 8.477 |